Thanks, Trip.
Our mission to care standards eye that seeing. the keep is to develop of providers allow empowering procedurally transformative to care, interventional people technologies elevate
advancements technologies ability the bolster in success initiatives is improve value will providers to supporting been there on of optometry and long they and to term. the their the rely Recently, our eye help with Our contingent care for lives provide ophthalmology our have patients. on strategic that
while used of in eye disease. market-tested procedures, and care, dry used has and in XXX,XXX been interventional eye over X TearCare that problems dry XX,XXX procedures. TearCare glaucoma X developed have technologies in in We glaucoma over has OMNI address biggest care, OMNI eye the been
draft These that to our our demonstrated mid-November, of Omni's on focusing effective the With will local to single with both this and mix and critical Medicare as us Site year administrative for much is published has the continued confirm ensuring performed development, continue and Starting our in we or of segment. will growth franchise X commercial that procedures support determinations, product with technologies, in position our beyond. and help establish market both company This a equitable cataract and have with both Medicare coverage access June work growth XXXX review surgery The coming the in access. strategy LCDs, for high-quality, that of contractors profile Sciences glaucoma we've lay progress the made strong years. to will eye long-term organization care optimization been been a clinical market developments for and of interventional support market foundation coupled procedure, fit by coverage technologies surgical a for differentiated a canaloploty fronts. surgical procedures. this year were on peer established both leading become including X over good data continued goniotomy with glaucoma believe
the While restrictions also impact to some on procedures. the be that we mix are this have pleased of to inclusion reimbursement combination clarity, the device Medicare will we there market growth with recognize rate mixed
allowed of new total goods or the a MIGS procedure X choose instead, secondary MIGS to approximately with will and in procedures secondary have that XX% not surgeon is mixed LCDs will time. estimate Our be under procedures Those build another combination build at code. a the
for headwind to expect we OMNI this over growth we Omni's devices, impact MIGS lapped. procedure strong is this efficacy, market surgeons until expect profile provide to comprehensive regularly While a and other case that compelling choose
and to under status payment procedure final We not payment did our is limitations issued OMNI XXXX performed with the procedure of in proposed on long with I comprehensive market rule hospitals see headwind surgical differentiator with combination with access, OMNI a the were rule glaucoma term, that short rule believe MIGS procedures on will X. for assign a ASCs comment July, for the the Sticking technology. to procedures code profile. issued disappointed XXXX year XXXXX, this its a device-intensive also unlike want While be the CPT to November code final associated in that calendar that term, Medicare was we on build
the assign device-intensive to necessary XX% fell the status. rule, final the device In code threshold reported costs under
Medicare has the of to to close very in We CPT-XXXXX facility by for determination are to final X% the threshold. omni cost the increase rates device for CMS' device-intensive Medicare been calculation by for for was this year. CMS. X% Medicare XXXX, the compared We and plan this will for OPD and the or categorization costs stakeholders $XXX procedures in a prior by about XX.XX% for Based basis ASC offset closely more the properly device Device-intensive increase facility pursue a the status status will our company. rate OMNI on to initiative working believe rule ensure as or reported the to hospital are the and to continue evaluating amount with about we rates is compared appropriate to comprehensive the device-intensive procedures final payment rate $XX XXXX to the ensure and ASC. long-term
maintain XXXX involved are but [indiscernible] with to important we decrease to believe still stent, for In addition, more fees slight Medicare a rate procedures like surgeons. is rates professional overall the differentials similar goniotomy versus which
feel can the execute still plans existing in we like we our reimbursement growth So environment.
increase same revenue higher the our the Revenue We from $XX.X X% recovery Now turning versus expectations quarter. the by year. not performance, in total growth partially LCDs, reflecting due surgical million, to meet our prior third glaucoma revenue to offset of a to of the period and did dry slower-than-expected generated representing million, revenue and for compared decline compared sequential was X. quarter eye of quarter X% demand price an by third revenue $XX.X of XXXX. of effective of of October to a glaucoma TeerCare/Smart X% the Surgical driven increase Lids ahead XXXX the second
and second LCD to in expected faster the raised commercial The bar excellence deliver the recovery the third lower temporary sales process the performance our compared better of than has While the level execution a short period from quarter the of utilization by environment uncertainty quarter required we'd during on LCDs team we a our ongoing expected from fell of LCD coverage [indiscernible] we to plan. seasonality, due our experienced
Our on to expectations. disrupted recovery
While expected. their quickly these LCDs, haven't the following levels utilization recovered than territories others is utilization, recovered and of lower many as final to territories pre-LCD in the issuance of
of included a LCDs with less may LCD our and of counter devices trialing allowed effective more selling we'd a that periods. challenging competitive consistency Given this our period likely uncertainty. period, process recovery trialing overestimated more territories commercially This overall immediate from We've disruptive on have emerging pace the elevated lower-priced and across of LCD experienced recovery. also prior during the focus our intense team in coverage during than
grow the results this effectively fit continue our the sales optimize growth. at is organization the of environment are We we look our intact to to sales reps very fundamentals value performance market articulating well our continuing and which Despite in within OMNI by established. much drive dynamic are business. areas Many performing to and the can product quarter, clearly force stronger and
the However, in we expected period, this root this causes a each underperformance of LCD during below addressing are portion and market. performing levels are
we effectively changes performance, to execution territory impact on growing. until greater having some competing layers continuing of co-function enhance have remain making believe to and commercial performance to our Over an we certain and are key across all the and already a are been consistency of enhancements past driving consistency but several these level country. and organizational to months, territories We and organization the optimize focused our leadership certain
to coverage the to are month and coupled within operate effectiveness made better over stabilize organizational normal us stabilized the past position with performance predictability. and quarters commercial this have to for of and later with the few new we expect come enhancements us We environment LCD confident, clarity provides final the that for clarity we
to reaccelerate training decreased lead that with all our increasing increased competitive of and [indiscernible]. OMNI growth, surgeon pipeline new In commercial across our addition believe orders we positioning have utilization on we organization increased our accounts are stand-alone with to engagement improving focused accounts reengagement an new to accounts, surgeons enhancements, market on and growth, will which
to strong actively the on positioning align our efficacy competitive We with are working OMNI. of evolving clinical
in navigate With proven preferred surgical working option We priority. we trends safety to believe and on mix their OMNI treatment our accounts are segment. medication should new with how combination are earned for a efficacy without environment to patients, patients be the have this, to burden who in a positive why more growth and mix on Medicare as reduce proactive glaucoma
Now moving to accounts. reengagement with
'XX, updates has been slower Following LCDs MIG XXXX at LCD following expected. issued than to resulting reengagement from draft
have accounts reduced LCD in omni particularly or periods omni We reengaging accounts been lost as their devices utilization, but are of process. trialing those the focused that which ENGAGE during identified have on in frequent recent historically the users,
but training with the LCD XXXX, before rate was quarterly historic averages run period. line our surgeon New for in below uncertainty
the LCDs, our will to strategy new the be base over also on technology. support following of half that the growing we surgeons States.
Further, in surgeons coverage There believe MIG-trained opportunity we than making remains forward surgeons we of our less our look train significant trained the we improvements Given finalized in United believe the trained stand-alone growth are our have time. to we as
think continue shift procedural how to on see patients to in a care the and about We treating intervention. physicians continuum
look at in on have have procedure the a OMNI landscape compelling a the We and care stand-alone the for address the to the drainage proposition taken continuum down comprehensive to deeper population all specific value nature cases ability patient drill X evolving of areas and whom residence in MIG the pathway. its due of
for effectively CPT-XXXXX these patients, for procedures. device-intensive receive can not these surgical segment, be the In we our riskier surgery, utilized glaucoma a invasive need and segment and these well thus disappointed potentially later-stage that on OMNI consists while believe conclusion or who of but are of is we or the more that with of advanced were on with not surgical intervention did out status, coverage of surgery, cataract on Most strategy complicated us from medications, our a for in trabeculectomy X risk organization are focus heightened or glaucoma stand-alone post on patient coupled controlled had return MIGS finalized prior an believe whose MIGS performed patients have like and way disease we procedure LCDs for their may position LCDs This confirmed at patients years at execution procedure to progression. to cataract X time the growth. more and the shunt to improvements IOP deli
OMNI goals and adoption further our for drive remain cases and quarter We of meet combination confident fourth XXXX. and expect differentiated clinically in in execution use to technologies our strengthen trajectory to cataract XXXX organizational both the commercial in into the and resumed surgical stand-alone of glaucoma growth
drops. standard awareness of we Now our to market notably towards the value SAHARA eye TearCare, work prescription impact RCT achieving analysis business. continue With dry economic eye assets, of that long-term to the payer XX-month care I'll demonstrates clinical and budget interventions to turn equitable of and advance TearCare driving health relative our our results
establish three-pronged dry executing a superior market-leading of developing best-in-class and developed approach, supported establishing our includes have mission long-term our position. This MDD TearCare technology, business, with U.S. equitable we long-term for market associated pioneering the dry of disease. which provide time effective market eye around resources XX and we our interventional working We diagnosed solution have inception an to strategy the to outcomes field eye strategy a believe estimated of by dedicated patients a the facilitate and Since to technology dry will reimbursed clinical reimbursement. eye the access million RCTs delivering building and
treatment the conversations we the to We've budget analysis, impact existing cost introducing with of estimates a formulary budget our part been specific in payers, within which the important the coming The it or savings listing analysis showcases as published results over of which treatment submission. technology impact and be manufacturer's options. expect a and months therefore, is the reimbursement a adopting outcomes or of environment, provider key a fiscal is new
continue to plans. and our are we the we be Car hubs, that had care number progress with payment by invested eye have our to trained launch. performed policies. With is broad strong through to Care This toward paid health the and since our payers, X,XXX over payment business some decisions we encouraged policy we start TearCare on coverage feel XX,XXX in have positioned coverage in clinical and Once TearCare doing continue and the well tracking believe can We wins, we economics and have and/or Medicare insurance we on hand, of focus advance work commercial establishing data expectations, a in activate claims procedure will been to who dry procedures reimbursement TearCare conversations by eye is over providers team XXXX. we drive and
significant pleased stronger highlighting eye in patients. also a third TearCare and with eye interest were expected, results saw dry our eye providers quarter compelling solution demand in We than very customer their as dry care for
as that we added additional I'm innovation, talent XX of President, innovations development Vice leadership Next Raheja the Vision, Optics, Bausch+Lom. to Lastly, over experience Vice He than Abbott companies Research Chief M.K. more within with nearly TepoVision as and Officer to President, Johnson to global technology XX experience and Executive Sciences Taylor, at Executive from in product years industry-leading development manufacturing. appointment Technologies Engineering has served device medical and announce overseeing ophthalmic excited Sight past also our and bringing have Operations. Development; such Brenton Inogen, innovation, XX M.K. ophthalmology and recently ophthalmic has & of EVP R&D organizations, of Johnson in team market and was as Dr. medical operations and a Medical Inc. at Brenton as and Energy overseeing years energy most recently Executive Co-Founder roles
plans our to capabilities. dedicated and will with bring development, to a vast will Separating significant existing the years. our with and infrastructure skill experience further tech Brenton the support M.K. ensure we strategic profitable contribute over appropriate pipeline growth and executive coming advancing the have team's functions scale to operation Both unique set that med R&D enhance resources
to I'll TearCare, now continued accelerate in to ahead, including in in Looking first and on dry and opportunity developments gives in XXXX. growth over ample our turn Ali expected XXXX recent MIGS the clarity, the XXXX, discuss in recent reimbursed call financials. capability momentum and goals executive LCD us hires to interventional the team execute mover eye making our
